A long-term care center interdisciplinary education program for antipsychotic use in dementia: Program update five years later

International Psychogeriatrics

Volumn 24, Issue 4, 2012, Pages 599-605

  Vida, Stephen ^a,b   Monette, Johanne ^a,c   Wilchesky, MacHelle ^a,c   Monette, Michèle ^a,c   Friedman, Ruby ^a,c   Nguyen, Anh ^a   Dastoor, Dolly ^d   Cristache, Gabriela ^a   Sourial, Nadia ^c   Tremblay, Lucie ^a   Gore, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

antipsychotic agents; dementia; geriatrics; long term care; prescribing educational program; prescribing intervention

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; AGGRESSIVENESS; AGITATION; ARTICLE; BEHAVIOR DISORDER; DEMENTIA; EDUCATION PROGRAM; FEMALE; HUMAN; INTERDISCIPLINARY EDUCATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME BEHAVIOR PROBLEMS SCALE; NURSING HOME PATIENT; PSYCHOSIS; RATING SCALE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; FEMALE; GERIATRIC PSYCHIATRY; HUMANS; LONG-TERM CARE; MALE; NURSING HOMES; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84859068178     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610211002225     Document Type: Article

References (30)

1. Ballard, C. et al. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine, 5, e76.
2. Ballard, C. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151-157.
3. Burke, W. J. (1991). Neuroleptic drug use in the nursing home: the impact of OBRA. American Family Physician, 43, 2125-2130.
4. Canadian Pharmacists Association (2011). Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association.
5. Centers for Medicare and Medicaid Services (2006). Revised Long-Term Care Facility Resident Assessment Instrument User's Manual. (Rev. 70, 01-07-11). Available at: .
6. Chen, Y., Briesacher, B. A., Field, T. S., Tjia, J., Lau, D. T. and Gurwitz, J. H. (2010). Unexplained variation across US nursing homes in antipsychotic prescribing rates. Archives of Internal Medicine, 170, 89-95.
7. Institute of Medicine, Committee on Nursing Home Regulation. 1986). Improving the Quality of Care in Nursing Homes. Washington, DC: National Academy Press.
8. Jeste, D. V., Rockwell, E., Harris, M. J., Lohr, J. B. and Lacro, J. (1999). Conventional vs. newer antipsychotics in elderly patients. American Journal of Geriatric Psychiatry, 7, 70-76.
9. Kamble, P., Chen, H., Sherer, J. and Aparasu, R. R. (2008). Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 6, 187-197.
10. Knol, W., Van Marum, R. J., Jansen, P. A., Souverein, P. C., Schobben, A. F. and Egberts, A. C. (2008). Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society, 56, 661-666.
11. Lee, P. E. et al. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of the American Geriatrics Society, 53, 1374-1379.
12. Liperoti, R. et al. (2005). Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696-701.
13. Monette, J. et al. (2008). Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry, 23, 574-579.
14. Monette, J., Monette, M., Champoux, N., Galbaud Du Fort, G. and Wolfson, C. (2009). Efficacy and adverse effects of antipsychotic medications among elderly persons with dementia. La Revue de Gériatrie, 23-31.
15. Ostini, R. et al. (2009). Systematic review of interventions to improve prescribing. Annals of Pharmacotherapy, 43, 502-513.
16. Ray, W. A., Blazer, D. G., Schaffner, W. and Federspiel, C. F. (1987). Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. American Journal of Public Health, 77, 1448-1450.
17. Ray, W. A., Taylor, J. A., Lichtenstein, M. J. and Meader, K. G. (1992). The Nursing Home Behavior Problem Scale. Journal of Gerontology, 47, 9-M16.
18. Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K. and Murray, K. T. (2001). Antipsychotics and the risk of sudden cardiac death.[see comment]. Archives of General Psychiatry, 58, 1161-1167.
19. Roberts, M. S. et al. (2001). Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. British Journal of Clinical Pharmacology, 51, 257-265.
20. Rochon, P. A. et al. (2005). Atypical antipsychotics and parkinsonism. Archives of Internal Medicine, 165, 1882-1888.
21. Rochon, P. A. et al. (2007). Variation in nursing home antipsychotic prescribing rates. Archives of Internal Medicine, 167, 676-683.
22. Ruths, S., Straand, J., Nygaard, H. A., Bjorvatn, B. and Pallesen, S. (2004). Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. Journal of the American Geriatrics Society, 52, 1737-1743.
23. Ruths, S., Straand, J., Nygaard, H. A. and Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study. The Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889-895.
24. Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934-1943.
25. Schneider, L. S. et al. (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 1525-1538.
26. Semla, T. P., Palla, K., Poddig, B. and Brauner, D. J. (1994). Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. Journal of the American Geriatrics Society, 42, 648-652.
27. Thapa, P. B., Meador, K. G., Gideon, P., Fought, R. L. and Ray, W. A. (1994). Effects of antipsychotic withdrawal in elderly nursing home residents. Journal of the American Geriatrics Society, 42, 280-286.
28. Trifiro, G., Spina, E. and Gambassi, G. (2009). Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacological Research, 59, 1-12.
29. Weiden, P. J. (2007). EPS profiles: the atypical antipsychotics are not all the same. Journal of Psychiatric Practice, 13, 13-24.
30. Westbury, J., Jackson, S., Gee, P. and Peterson, G. (2010). An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. International Psychogeriatrics, 22, 26-36.